The relationship between atrial fibrillation and erectile dysfunction is one of the more under-discussed intersections in men's cardiovascular medicine. Atrial fibrillation is the most common sustained arrhythmia in adults, affecting an estimated 1 to 2 percent of the general population and rising steeply after age 60. Erectile dysfunction follows a similar age curve and shares most of the same antecedents: hypertension, diabetes, obesity, obstructive sleep apnea, and chronic systemic inflammation. When the two appear in the same patient, it is tempting to treat the overlap as coincidence — two common conditions in an aging man. The published evidence suggests the association is tighter than chance, and that the direction of the relationship runs both ways.
The Epidemiological Signal
The clearest quantitative picture comes from two systematic reviews published within a year of each other. A 2018 meta-analysis in the International Journal of Urology pooled observational cohorts examining erectile dysfunction and atrial fibrillation and found a consistent positive association between the two conditions across study populations, with the relationship persisting after adjustment for shared cardiovascular risk factors [1]. A second meta-analysis, published in the Arab Journal of Urology in 2019, approached the question from the opposite direction and reported that baseline atrial fibrillation was itself associated with an increased subsequent risk of erectile dysfunction, with pooled estimates indicating roughly a 1.5-fold elevation in risk compared with men in sinus rhythm [2].
Observational associations of this kind are always vulnerable to confounding, because the conditions that cause atrial fibrillation also cause erectile dysfunction. A 2023 Mendelian randomization analysis published in Frontiers in Cardiovascular Medicine attempted to address that problem by using genetic variants as instrumental variables, and reported evidence supporting a causal contribution of cardiovascular disease — including heart failure and coronary artery disease — to erectile dysfunction risk [3]. The genetic evidence for atrial fibrillation specifically is weaker than for coronary disease, which is an honest limitation of the current literature. What the combined data support is a strong, probably partly causal, and clinically meaningful association rather than a proven direct causal chain from arrhythmia to erectile failure.
Shared Biology: Endothelium, Inflammation, and Autonomic Tone
The mechanistic case rests on three overlapping systems.
The first is endothelial function. Erection depends on nitric oxide released from vascular endothelium and nerve terminals in the corpora cavernosa, which raises cyclic GMP in smooth muscle and permits the arterial dilation and sinusoidal filling that produce rigidity. Atrial fibrillation is associated with measurable endothelial dysfunction, including reduced flow-mediated dilation and elevated markers of oxidative stress. The penile arteries are small — roughly 1 to 2 millimetres in diameter — and a given percentage loss of endothelial reserve produces a larger functional deficit there than in the coronary or carotid circulation. This is the anatomical reason erectile dysfunction frequently precedes other cardiovascular events by several years.
The second is inflammation and atrial remodeling. Elevated C-reactive protein, interleukin-6, and tumour necrosis factor alpha are characteristic of both atrial fibrillation substrate and vasculogenic erectile dysfunction. Inflammatory signalling reduces nitric oxide bioavailability directly, through increased superoxide production and uncoupling of endothelial nitric oxide synthase, while simultaneously promoting the atrial fibrosis that sustains the arrhythmia.
The third is autonomic imbalance. Atrial fibrillation is associated with increased sympathetic tone and reduced heart rate variability. Erection is a parasympathetically initiated event; sustained sympathetic dominance raises cavernosal smooth muscle tone and opposes the relaxation required for tumescence. The same autonomic profile that destabilises atrial electrical activity also biases penile vascular tone toward detumescence.
To these should be added hemodynamics. Loss of organised atrial contraction removes the atrial contribution to ventricular filling — commonly cited as 15 to 30 percent of stroke volume — and an irregular rhythm produces beat-to-beat variability in cardiac output. In men with limited cardiac reserve, this reduces the perfusion pressure available to a vascular bed that already operates near its threshold.
The Medication Confound
Any discussion of atrial fibrillation and erectile dysfunction has to account for drug effects, because men with atrial fibrillation are rarely on no medication.
Beta-blockers, used for rate control, have the longest-standing association with sexual side effects. The effect appears to be partly pharmacological and partly expectation-driven: trials in which patients were blinded to the identity of the drug have reported substantially lower rates of reported erectile dysfunction than open-label use. Thiazide diuretics carry a reasonably consistent signal. Among antiarrhythmics, amiodarone and digoxin have both been linked to sexual dysfunction, digoxin plausibly through effects on sodium-potassium ATPase in cavernosal smooth muscle and on sex hormone binding.
Anticoagulation deserves separate comment because it is the most common source of patient anxiety. Direct oral anticoagulants and warfarin are not known to impair erectile physiology. What they can do is alter the risk calculus around any procedural intervention and, in some men, contribute to a generalised sense of fragility that suppresses sexual confidence. That psychological pathway is real and worth naming in consultation, but it is not a pharmacological effect on erectile tissue.
The clinical implication is that erectile dysfunction appearing after a new atrial fibrillation diagnosis should prompt a medication review before it is attributed to the arrhythmia itself. Rate-control strategies can often be adjusted, and some men experience improvement when a non-selective beta-blocker is exchanged for a vasodilating agent such as nebivolol.
What Happens When Rhythm Is Restored
If the arrhythmia contributes causally, restoring sinus rhythm should improve erectile function. A 2024 report in JACC: Clinical Electrophysiology examined this directly, analysing erectile dysfunction medication dependency in men undergoing catheter ablation for atrial fibrillation. The authors reported improvement in erectile function following successful ablation, including reduced reliance on erectile dysfunction pharmacotherapy in a proportion of patients [4]. The study is small and non-randomised, and part of the benefit is plausibly attributable to discontinuation of rate-control drugs after ablation rather than to rhythm restoration alone — a confound the medication-dependency framing makes visible rather than resolving.
Taken cautiously, the finding supports a practical point: erectile dysfunction in a man with atrial fibrillation is not necessarily fixed. It can respond to better management of the underlying arrhythmia and its risk substrate, particularly where sleep apnea, obesity, alcohol intake, and uncontrolled hypertension are driving both conditions.
Using PDE5 Inhibitors When You Have Atrial Fibrillation
Phosphodiesterase type 5 inhibitors — sildenafil, tadalafil, vardenafil — are not contraindicated in atrial fibrillation as such. They were developed as cardiovascular drugs, and their systemic vasodilatory profile is modest: typical reductions of 8 to 10 mmHg systolic in healthy volunteers.
The absolute contraindication is concurrent nitrate therapy in any form, including sublingual glyceryl trinitrate and isosorbide preparations, where the combination can produce profound hypotension. Alpha-blockers require dose separation and medical supervision. Men on amiodarone or other QT-prolonging antiarrhythmics warrant individual assessment. Anyone with recent myocardial infarction, unstable angina, decompensated heart failure, or significant aortic stenosis needs cardiology input before starting, and the Princeton consensus framework for stratifying cardiac risk before resuming sexual activity remains the standard reference for that conversation.
Within those boundaries, the outcome data are reassuring and arguably favourable. A Swedish cohort study published in Heart in 2017 followed men after myocardial infarction and found that treatment for erectile dysfunction with PDE5 inhibitors was associated with lower mortality and lower risk of heart failure hospitalisation compared with no treatment [5]. A separate Heart analysis in 2016 reported that PDE5 inhibitor use in men with type 2 diabetes was associated with a reduction in all-cause mortality [6]. Neither is a randomised trial, and both are open to the criticism that healthier men are more likely to be prescribed these drugs and more likely to be sexually active in the first place. But the consistent direction across large cohorts argues strongly against the older assumption that these medications are a cardiac liability.
The operative requirement is supervision. A man with atrial fibrillation has a medication list, a rhythm-control strategy, and usually an anticoagulant, and treatment decisions need to be made against that full picture rather than in isolation.
Conclusion
Atrial fibrillation and erectile dysfunction are linked through endothelial dysfunction, systemic inflammation, autonomic imbalance, and reduced hemodynamic efficiency, with medication effects layered on top. Meta-analytic data support a consistent association in both directions, and early procedural data suggest erectile function may improve when sinus rhythm is restored. For the individual patient, the practical sequence is unchanged: review the medication list, address the shared risk factors — sleep apnea, alcohol, weight, blood pressure — and treat the erectile dysfunction on its own terms once cardiac risk has been stratified. Erectile dysfunction in this population should also be read as a vascular signal worth investigating rather than a nuisance symptom, a point covered in more depth across our blog.
If you're exploring clinically-formulated options, OnyxMD offers physician-supervised treatment plans starting with a free online assessment at questionnaire.getonyxmd.com, including Red Pill, an on-demand formulation pairing tadalafil with pycnogenol for men whose cardiologist has cleared them for treatment.
These statements have not been evaluated by the FDA. This content is for informational purposes only and does not constitute medical advice.
References
Chokesuwattanaskul R, Thongprayoon C, Pachariyanon P, Sharma K, Ungprasert P, Bathini T, Cheungpasitporn W. Erectile dysfunction and atrial fibrillation: a systematic review and meta-analysis. International Journal of Urology. 2018;25(8):752-757. doi:10.1111/iju.13725
Prasitlumkum N, Kewcharoen J, Kanitsoraphan C, Kittipibul V, Chongsathidkiet P, Rattanawong P. Baseline atrial fibrillation is a risk factor for erectile dysfunction: systematic review and meta-analysis. Arab Journal of Urology. 2019;17(2):98-105. doi:10.1080/2090598X.2019.1601001
Li Q, Long Q, Ren B, Bing S. Causal association between cardiovascular diseases and erectile dysfunction: a Mendelian randomization study. Frontiers in Cardiovascular Medicine. 2023;10:1094330. doi:10.3389/fcvm.2023.1094330
La Fazia VM, Massaro G, Mohanty S, Gianni C, Della Rocca DG, Torlapati PG, Horton R, Al-Ahmad A, Di Biase L, Natale A. Improvement of erectile dysfunction after atrial fibrillation ablation: a medication dependency analysis. JACC: Clinical Electrophysiology. 2024;10(12):2729-2731. doi:10.1016/j.jacep.2024.08.002
Andersson DP, Trolle Lagerros Y, Grotta A, Bellocco R, Lehtihet M, Holzmann MJ. Association between treatment for erectile dysfunction and death or cardiovascular outcomes after myocardial infarction. Heart. 2017;103(16):1264-1270. doi:10.1136/heartjnl-2016-310746
Anderson SG, Hutchings DC, Woodward M, Rahimi K, Rutter MK, Kirby M, Hackett G, Trafford AW, Heald AH. Phosphodiesterase type-5 inhibitor use in type 2 diabetes is associated with a reduction in all-cause mortality. Heart. 2016;102(21):1750-1756. doi:10.1136/heartjnl-2015-309223
Medical Disclaimer: The information provided on this website is for educational and informational purposes only and is not intended as medical advice. OnyxMD services should not be used to diagnose, treat, cure, or prevent any disease or medical condition. Always consult with a qualified healthcare provider before beginning any supplement regimen or health program.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Individual Results: Results may vary. The experiences and testimonials presented on this website are individual results that may not be typical. Your experience may be different.
Telehealth Services: OnyxMD provides telehealth services in 47 states (excluding AK, MS, NJ) through licensed healthcare providers via our partner Beluga Health, P.A. Services are subject to clinical evaluation and may not be appropriate for all individuals. Prescriptions fulfilled by Strive Pharmacy LLC (License #99-9817) and EPIQ SCRIPTS LLC.